1. Home
  2. AKRO vs HTH Comparison

AKRO vs HTH Comparison

Compare AKRO & HTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • HTH
  • Stock Information
  • Founded
  • AKRO 2017
  • HTH 1998
  • Country
  • AKRO United States
  • HTH United States
  • Employees
  • AKRO N/A
  • HTH N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • HTH Major Banks
  • Sector
  • AKRO Health Care
  • HTH Finance
  • Exchange
  • AKRO Nasdaq
  • HTH Nasdaq
  • Market Cap
  • AKRO 2.1B
  • HTH 2.0B
  • IPO Year
  • AKRO 2019
  • HTH 2004
  • Fundamental
  • Price
  • AKRO $32.15
  • HTH $30.55
  • Analyst Decision
  • AKRO Strong Buy
  • HTH Hold
  • Analyst Count
  • AKRO 7
  • HTH 3
  • Target Price
  • AKRO $43.20
  • HTH $34.50
  • AVG Volume (30 Days)
  • AKRO 505.3K
  • HTH 356.2K
  • Earning Date
  • AKRO 11-11-2024
  • HTH 10-24-2024
  • Dividend Yield
  • AKRO N/A
  • HTH 2.22%
  • EPS Growth
  • AKRO N/A
  • HTH N/A
  • EPS
  • AKRO N/A
  • HTH 1.63
  • Revenue
  • AKRO N/A
  • HTH $1,169,826,000.00
  • Revenue This Year
  • AKRO N/A
  • HTH N/A
  • Revenue Next Year
  • AKRO N/A
  • HTH $3.16
  • P/E Ratio
  • AKRO N/A
  • HTH $18.81
  • Revenue Growth
  • AKRO N/A
  • HTH N/A
  • 52 Week Low
  • AKRO $13.39
  • HTH $28.45
  • 52 Week High
  • AKRO $37.00
  • HTH $35.66
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 61.11
  • HTH 42.89
  • Support Level
  • AKRO $30.13
  • HTH $30.51
  • Resistance Level
  • AKRO $32.95
  • HTH $31.14
  • Average True Range (ATR)
  • AKRO 1.41
  • HTH 0.73
  • MACD
  • AKRO 0.13
  • HTH -0.04
  • Stochastic Oscillator
  • AKRO 75.44
  • HTH 22.61

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.

Share on Social Networks: